You just read:

BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18

News provided by

BrainStorm Cell Therapeutics Inc.

Jul 14, 2016, 15:30 ET